三维超声/超声造影-超声造影融合成像引导的肝脏肿瘤消融规划可行性:一项回顾性研究
本研究纳入2017年1月至2018年12月间接受经皮消融的82例患者共85个肝脏肿瘤,评估基于三维超声/超声造影与实时超声/超声造影融合成像进行消融规划的可行性。结果显示规划技术成功率100%,消融技术成功率100%,1个月后技术有效率为98.8%,局部肿瘤进展率5.9%(5/84),无严重并发症。作者认为该规划方法对肝脏肿瘤是可行的。
要点
- 三维超声/超声造影融合成像用于肝脏肿瘤消融规划,规划技术成功率100%(85/85)。
- 融合成像即时评估消融技术成功率100%,1个月CT/MR技术有效率98.8%(84/85)。
- 随访中局部肿瘤进展率5.9%(5/84),无严重操作相关并发症。
核心结论
- 基于三维超声/超声造影与实时超声/超声造影融合成像的消融规划对肝脏肿瘤是可行的。
研究设计与样本
- 回顾性研究,纳入2017年1月至2018年12月间接受经皮消融的82例患者共85个肝脏肿瘤。
- 术中行三维超声/超声造影成像进行消融规划,并以三维超声/超声造影与实时超声/超声造影融合成像引导规划实施。
- 术后1个月行增强CT/MR评估残留肿瘤,此后每3个月复查。
关键影像表现/征象
- 平均肝脏肿瘤直径为28±9 mm(范围10-55 mm)。
诊断标准与关键数值
- 三维超声/超声造影规划技术成功率为100%(85/85)。
- 融合成像即时评估消融技术成功率为100%。
- 术后1个月增强CT/MR显示1例肝内胆管癌患者存在残留肿瘤,技术有效率为98.8%。
- 中位随访21.5个月(IQR:4-36个月),局部肿瘤进展率为5.9%(5/84)。
临床应用与阅片要点
- 三维超声/超声造影与实时超声/超声造影融合成像可用于肝脏肿瘤消融的术前规划和术中引导。
- 融合成像可即时评估消融技术成功并提示是否需要补充消融。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the feasibility of ablation planning based on fusion imaging of three-dimensional ultrasound/contrast-enhanced ultrasound (3D US/CEUS) with real-time US/CEUS for liver tumor thermal ablation.
MATERIALS AND METHODS: Between January 2017 and December 2018, 85 hepatic tumors from 82 patients who underwent percutaneous ablation were included. First, intraprocedural 3D US/CEUS imaging was performed for ablation planning. Then, fusion imaging of 3D US/CEUS with real-time US/CEUS was used to guide the implementation of the plan, immediately evaluate the technical success and indicate the need for supplemental ablation. In addition, contrast-enhanced CT/MR imaging was performed 1 month after the procedure to evaluate the presence of residual tumors, and follow-up scans were repeated every 3 months.
RESULTS: The average liver tumor diameter was 28 ± 9 mm (range, 10-55 mm). 3D US/CEUS-based planning was successfully conducted in all 85 tumors with a 100% technical success rate of planning. The immediate evaluation by 3D CEUS/US-CEUS fusion imaging showed a 100% technical success rate of ablation. The 1-month CT/MR scans found a residual tumor in one intrahepatic cholangiocarcinoma patient; the technique efficacy rate was 98.8%. The median follow-up period was 21.5 months (IQR: 4-36 months). During the follow-up period, the local tumor progression rate was 5.9% (5/84), and no major procedure-related complications occurred.
CONCLUSIONS: Ablation planning based on 3D US/CEUS-US/CEUS fusion imaging is feasible for liver tumors.
引用
- You Y, Zhang M, Li K, et al. Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study. Abdom Radiol (NY). 2021. PMID: 33484284. doi:10.1007/s00261-020-02909-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。